[go: up one dir, main page]

MX2012015147A - Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. - Google Patents

Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.

Info

Publication number
MX2012015147A
MX2012015147A MX2012015147A MX2012015147A MX2012015147A MX 2012015147 A MX2012015147 A MX 2012015147A MX 2012015147 A MX2012015147 A MX 2012015147A MX 2012015147 A MX2012015147 A MX 2012015147A MX 2012015147 A MX2012015147 A MX 2012015147A
Authority
MX
Mexico
Prior art keywords
inflammatory
disorders
myelo
restricted
diseases
Prior art date
Application number
MX2012015147A
Other languages
English (en)
Inventor
Vatee Pattaropong
Todd J Kohn
Paul John Dransfield
Jillian L Simard
Felix Gonzalez Lopez De Turiso
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2012015147A publication Critical patent/MX2012015147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen heteroarilos bicíclicos sustituidos y composiciones que los contienen, para tratamiento de inflamación general, artritis, enfermedades reumáticas, osteoartritis, trastornos inflamatorios del intestino, trastornos inflamatorios del ojo, trastornos inflamatorios de la vejiga o de vejiga inestable, psoriasis, complicaciones de la piel con componentes inflamatorios, afecciones inflamatorias crónicas, incluyendo pero no restringido a. enfermedades autoinmunitarias tal como lupus eritematoso sistémico (SLE) , miastenia gravis, artritis reumatoide, encefalomielitis diseminada aguda, púrpura trombocitopénica idiopática, esclerosis múltiple, síndrome de Sioegren y anemia hemolítica autoinmunitaria, afecciones alérgicas incluyendo todas las formas de hipersensibilidad. La presente invención también permite los métodos para tratar cánceres que están mediados, dependen de o asociados con actividad p110, incluyendo pero no restringidos a leucemias, tal como Leucemia mieloide aguda (AML), Síndrome mielo-displástico (MDS), enfermedades mielo-proliferativas (MPD), Leucemia Mieloide Crónica (CML), leucemia linfoblástica aguda de células T (T-ALL), Leucemia Linfoblástica Aguda de Células B (B-ALL), Linfoma No de Hodgkins (NHL), linfoma de células 3 y tumores sólidos, tal como cáncer de mama.
MX2012015147A 2010-06-30 2011-06-30 Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. MX2012015147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36027810P 2010-06-30 2010-06-30
PCT/US2011/042539 WO2012003283A1 (en) 2010-06-30 2011-06-30 Heterocyclic compounds and their use as inhibitors of pi3k activity

Publications (1)

Publication Number Publication Date
MX2012015147A true MX2012015147A (es) 2013-05-01

Family

ID=44317919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015147A MX2012015147A (es) 2010-06-30 2011-06-30 Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.

Country Status (6)

Country Link
US (1) US20130090323A1 (es)
EP (1) EP2588471A1 (es)
AU (1) AU2011272862A1 (es)
CA (1) CA2803358A1 (es)
MX (1) MX2012015147A (es)
WO (1) WO2012003283A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
WO2015103355A1 (en) 2014-01-01 2015-07-09 Medivation Technologies, Inc. Compounds and methods of use
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109952303B (zh) * 2016-10-14 2022-10-21 林伯士拉克许米公司 Tyk2抑制剂及其用途
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
KR102613433B1 (ko) * 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004112710A2 (en) * 2003-06-17 2004-12-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
HRP20140147T1 (hr) * 2007-03-23 2014-03-28 Amgen Inc. 3-supstituirani derivati hinolina ili hinoksalina i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k)
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
CA2738429C (en) * 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EA201270051A1 (ru) * 2009-06-25 2012-05-30 Амген Инк. Гетероциклические соединения и их применения

Also Published As

Publication number Publication date
WO2012003283A1 (en) 2012-01-05
EP2588471A1 (en) 2013-05-08
US20130090323A1 (en) 2013-04-11
CA2803358A1 (en) 2012-01-05
AU2011272862A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
MX2012015135A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
WO2011123751A3 (en) Heterocyclic compounds and their use as pi3k inhibitors
MX2012015134A (es) Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
MX2013007261A (es) Compuestos heterociclicos y sus usos.
MX2011013667A (es) Compuestos heterociclicos y sus usos.
MX2011013666A (es) Compuestos heterociclicos y sus usos.
MX2012015143A (es) Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
MX2009009968A (es) Compuestos heterociclicos y sus usos.
MX2011013510A (es) Compuestos heterociclicos y sus usos.
MX2011013901A (es) Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2009009913A (es) Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2012015147A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2009010050A (es) Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
PH12014502246A1 (en) Heterocyclic compounds and their uses
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2017000331A (es) Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.
EP4219458A3 (en) Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
SA515370253B1 (ar) مركب أميد عطري غير متجانس الحلقة يحتوي على نتروجين ثنائي الحلقة
MX2016014483A (es) Nuevos compuestos utiles como inhibidores de s100.
CY1117196T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
AR090705A1 (es) Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
MX2016009624A (es) Compuestos heterobiciclicos novedosos como agonistas del opioide kappa.
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal